Quick Answer
Telomir Pharmaceuticals, Inc. reported Stockholders Equity of $5.91 million for the year ending 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +819.6% in Stockholders Equity from 2024 to 2025.
- This data is from Telomir Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$510.2 thousand | Q2 2023: $3.89 million | Q3 2023: $2.18 million | Q1 2024: $3.02 million | Q2 2024: $1.63 million | Q3 2024: $442.1 thousand | Q1 2025: -$161.1 thousand | Q2 2025: $481.2 thousand | Q3 2025: $6.98 million.
- Over the full 5 years of available data (2021 to 2025), Telomir Pharmaceuticals, Inc.'s Stockholders Equity has grown by 4,381.0%.
- Historical annual values: Fiscal year 2025: $5.91 million | Fiscal year 2024: $643.0 thousand | Fiscal year 2023: $3.44 million | Fiscal year 2022: -$937.3 thousand | Fiscal year 2021: -$138.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: